Literature DB >> 26374160

[Immunological Aspects in Oncology--Circulating γδ T Cells].

M Cibulka, I Selingerová, L Fědorová, L Zdražilová Dubská.   

Abstract

γδ T cells present a minor population of the T cell family which basically differs in construction of their T cell receptor (TCR). Thanks to the features of γδ TCR, these cells can acquire unique effector functions and play a specific role (not only) in antitumor immune response. In this article, we describe the basic characteristics of this cell population and their connection to cancer. In the experimental part we performed exploratory analysis of circulating γδ T cells in reference population and comparison with melanoma and breast carcinoma patients. The median percentage of γδ T cells from all lymphocytes was 2.9% (interquartile range-IQR 1.7-4%). The median absolute numbers of γδ cells per liter of blood was 5.05×10(7) (IQR 2.9-7.84×10(7)). The median percentage of γδ cells between all CD3 T cells was 3.9% (IQR 2.3-5.6%). No correlation between γδ T cells levels and gender or age was observed in reference population. Detailed immunophenotyping was also conducted describing representation of memory subsets (using CD45RO and CD27 markers) and presence of surface markers HLADr, CD69, CD25, CD28, CCR7, CTLA 4, ICOS, PD 1L and PD 1 between γδ T cells of the controls and breast carcinoma patients. From this analysis, it is evident that γδ T cells do not represent a uniform population but they differ in surface markers as well as in their effector functions.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26374160     DOI: 10.14735/amko20152s60

Source DB:  PubMed          Journal:  Klin Onkol        ISSN: 0862-495X


  2 in total

1.  Early Diagnosis of Tularemia by Flow Cytometry, Czech Republic, 2003-20151.

Authors:  Aleš Chrdle; Pavlína Tinavská; Olga Dvořáčková; Pavlína Filipová; Věra Hnetilová; Pavel Žampach; Květoslava Batistová; Václav Chmelík; Amanda E Semper; Nick J Beeching
Journal:  Emerg Infect Dis       Date:  2019-10       Impact factor: 6.883

2.  Assessment of Immune Response Following Dendritic Cell-Based Immunotherapy in Pediatric Patients With Relapsing Sarcoma.

Authors:  Lenka Fedorova; Peter Mudry; Katerina Pilatova; Iveta Selingerova; Jana Merhautova; Zdenek Rehak; Dalibor Valik; Eva Hlavackova; Dasa Cerna; Lucie Faberova; Pavel Mazanek; Zdenek Pavelka; Regina Demlova; Jaroslav Sterba; Lenka Zdrazilova-Dubska
Journal:  Front Oncol       Date:  2019-11-14       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.